Save information for later
Sign Up

Learn About Dyskeratosis Congenita

What is the definition of Dyskeratosis Congenita?
Dyskeratosis congenita (DC), a telomere biology disorder, is characterized by a classic triad of dysplastic nails, lacy reticular pigmentation of the upper chest and/or neck, and oral leukoplakia. The classic triad may not be present in all individuals. People with DC are at increased risk for progressive bone marrow failure (BMF), myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML), solid tumors (usually squamous cell carcinoma of the head/neck or anogenital cancer), and pulmonary fibrosis. Other findings can include: abnormal pigmentation changes not restricted to the upper chest and neck, eye abnormalities (epiphora, blepharitis, sparse eyelashes, ectropion, entropion, trichiasis), and dental abnormalities (caries, periodontal disease, taurodauntism). Although most persons with DC have normal psychomotor development and normal neurologic function, significant developmental delay is present in the two variants in which additional findings include cerebellar hypoplasia (Hoyeraal Hreidarsson syndrome) and bilateral exudative retinopathy and intracranial calcifications (Revesz syndrome). Onset and progression of manifestations of DC vary: at the mild end of the spectrum are those who have only minimal physical findings with normal bone marrow function, and at the severe end are those who have the diagnostic triad and early-onset BMF.
Who are the top Dyskeratosis Congenita Local Doctors?
Elite in Dyskeratosis Congenita
Pediatric Hematology Oncology
Elite in Dyskeratosis Congenita
Pediatric Hematology Oncology
10 Center Drive, National Institutes Of Health Clinical Center, 
Bethesda, MD 
Languages Spoken:
English

Sharon Savage is a Pediatric Hematologist Oncology provider in Bethesda, Maryland. Dr. Savage is rated as an Elite provider by MediFind in the treatment of Dyskeratosis Congenita. Her top areas of expertise are Dyskeratosis Congenita, Aplastic Anemia, Aase Syndrome, Bone Marrow Transplant, and Hormone Replacement Therapy (HRT).

Elite in Dyskeratosis Congenita
Pediatric Hematology Oncology
Elite in Dyskeratosis Congenita
Pediatric Hematology Oncology
9609 Medical Center Dr, Room 6e452, 
Rockville, MD 
Languages Spoken:
English

Blanche Alter is a Pediatric Hematologist Oncology provider in Rockville, Maryland. Dr. Alter is rated as an Elite provider by MediFind in the treatment of Dyskeratosis Congenita. Her top areas of expertise are Aase Syndrome, Dyskeratosis Congenita, Aplastic Anemia, Bone Marrow Transplant, and Hormone Replacement Therapy (HRT).

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Dyskeratosis Congenita
Elite in Dyskeratosis Congenita
Aachen, NW, DE 

Fabian Beier practices in Aachen, Germany. Mr. Beier is rated as an Elite expert by MediFind in the treatment of Dyskeratosis Congenita. His top areas of expertise are Dyskeratosis Congenita, Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Anemia, and Bone Marrow Transplant.

What are the latest Dyskeratosis Congenita Clinical Trials?
Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study

Background: A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders. Pathogenic variant(s) in IBMFS genes are relevant to carcinogenesis in sporadic cancers. Patients with IBMFS who develop cancer differ in their genetic and/or environmental features from patients with IBMFS who do not develop cancer. These cancer-...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Nucleoside Therapy in Patients With Telomere Biology Disorders

Summary: The goal of this clinical trial is to learn if a combination therapy of deoxycytidine (dC) plus deoxythymidine (dT) is safe in patients with telomere biology disorders. The main questions it aims to answer are: * Is the therapy safe with tolerable side effects in patients with telomere biology disorders? * Are problems with the bone marrow or blood or lungs changed after 6 months of dC+dT treatmen...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center